SecBot SecBot
8-K ·Filed Aug 10, 2026

PROK

PROKIDNEY CORP.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001193125-26-342397
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on PROACT 1 enrollment completion and the Q2 2027 topline readout timeline, not on quarterly financials. Monitor for any updates on the confirmatory full enrollment (~470 patients) expected in H2 2026 and any regulatory interactions that could derisk the accelerated approval pathway.

DirectionNeutral
Confidencehigh
Horizonmonths

REACT

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

Price Chart

Loading chart...

Executive Summary

ProKidney reported Q2 2026 results with no revenue or EPS surprises vs consensus, as the company remains a pre-commercial clinical-stage biotech. The key catalyst is the completion of enrollment for the PROACT 1 accelerated approval analysis (~320 patients), positioning the company for pivotal eGFR slope topline results in Q2 2027. Cash burn continues with $181.6M in cash supporting operations into mid-2027, and the net loss widened to $46.4M from $37.0M YoY.

Key Financial Metrics

EPS
−$0.15
est −$0.13 · -15.4%
Revenue
$150.0K
est $149.0K · +0.7% · -32.1% YoY
Rating
in line

Key Facts

  • Completed enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis; pivotal topline results expected Q2 2027
  • Cash, cash equivalents and marketable securities totaled $181.6M as of June 30, 2026, down from $224.9M at March 31, 2026
  • Net loss before noncontrolling interest was $46.4M for Q2 2026 vs $37.0M for Q2 2025
  • R&D expenses increased to $36.1M from $25.9M YoY, driven by PROACT 1 clinical costs
  • Appointed Kenneth Locke as Chief Technical Officer in June 2026

Financial Impact

No revenue or EPS surprise; cash burn of ~$43M per quarter; cash runway into mid-2027

cashnet lossR&D expenses

Risk Factors

  • Clinical trial failure or negative eGFR slope results in Q2 2027
  • Cash runway only into mid-2027, requiring future dilutive financing
  • Regulatory risk: FDA may require additional studies before BLA acceptance

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342397
Document: prok-20260810.htm0001193125-26-342397
Document: 0001193125-26-342397-index-headers.html0001193125-26-342397
Document: 0001193125-26-342397-index.html0001193125-26-342397
Document: 0001193125-26-342397.txt0001193125-26-342397
8-K Data (Synthetic)0001193125-26-342397

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 Viewing No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026